Pramlintide
Fat LossFDA-approved amylin analogEstablished
FDA-approved amylin analog (Symlin) used with mealtime insulin in type 1 and type 2 diabetes. Hypoglycemia risk requires insulin dose reduction.
For research use only.
Key Facts
- CAS
- 151126-32-8
- Molecular Weight (MW)
- 3949.4 g/mol
- Half-life
- ~48 minutes
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Before major meals
- Last updated
- 8/23/2026
- Targets
- Amylin receptor
Overview
FDA-approved amylin analog (Symlin) used with mealtime insulin in type 1 and type 2 diabetes. Hypoglycemia risk requires insulin dose reduction.
Protocol
- Dosage Range
- T1D typically 15–60 mcg before meals; T2D 60–120 mcg (label)
- Frequency
- Before major meals
- Cycle
- Chronic with insulin as prescribed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Amylin-receptor agonist that delays gastric emptying, reduces postprandial glucagon, and increases satiety. Used only as an adjunct to insulin.
Targets
Amylin receptor
Studies
- Pramlintide with insulin— Journal/year not available
Benefits
Postprandial glucose adjunctSatiety with insulin regimens
Potential Side Effects
- Nausea
- Severe hypoglycemia with insulin
References
- Symlin labelExternal link · Year —